Corcept Therapeutics Incorporated or Dynavax Technologies Corporation: Who Manages SG&A Costs Better?

Corcept vs. Dynavax: SG&A Cost Efficiency Battle

__timestampCorcept Therapeutics IncorporatedDynavax Technologies Corporation
Wednesday, January 1, 20143491600017763000
Thursday, January 1, 20153694900022180000
Friday, January 1, 20164524000037257000
Sunday, January 1, 20176241600027367000
Monday, January 1, 20188128900064770000
Tuesday, January 1, 201910035900074986000
Wednesday, January 1, 202010532600079256000
Friday, January 1, 2021122356000100156000
Saturday, January 1, 2022152848000131408000
Sunday, January 1, 2023184259000152946000
Loading chart...

Unveiling the hidden dimensions of data

SG&A Cost Management: Corcept vs. Dynavax

In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Corcept Therapeutics Incorporated and Dynavax Technologies Corporation, two prominent players, have shown distinct trends in their SG&A expenditures over the past decade.

From 2014 to 2023, Corcept's SG&A expenses surged by approximately 428%, reflecting their aggressive expansion and investment in administrative capabilities. In contrast, Dynavax's expenses increased by about 761%, indicating a more rapid scaling of operations. Despite this, Corcept consistently maintained lower SG&A costs relative to revenue, suggesting more efficient cost management.

By 2023, Corcept's SG&A expenses reached 184 million, while Dynavax's were 153 million, highlighting Corcept's larger scale. Investors and stakeholders should consider these trends when evaluating the financial health and strategic direction of these companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025